A decade ago, I purchased a fireproof lockbox to secure important papers, such as birth certificates, Social Security cards, and passports. I also stored several necklaces that my husband, Todd, had given to me, along with two watches he’d worn before he got ALS. Over the years, I added…

Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, a small study reports. It also stabilized patients’ quality of life and lowered levels of nerve damage-related biomarkers, which is consistent with clinical trial data that…

A double-blind Phase 2 clinical trial that will test Corcept Therapeutics’ oral cortisol modulator dazucorilant against a placebo in people with amyotrophic lateral sclerosis (ALS) is now fully enrolled, the company announced in a press release. Called DAZALS (NCT05407324), the trial involves 249 adults with sporadic…

ALS was first identified in 1869, though its symptoms were documented in medical literature as early as 1824. It’s intriguing that the sequence of the disease today is often similar, with initial symptoms followed by an actual diagnosis. It took four years to receive my…

My husband, Todd, woke to double vision after a week of severe headaches. He was discouraged because his vision was one thing he had left after 14 years of ALS taking most of his muscles. I scheduled an appointment for him to see an ophthalmologist on Monday of last…

Stem cell therapy, specifically treatment with mesenchymal stem cells or MSCs, did not substantially alter disease progression among people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2 clinical trial. However, there was a subset of patients who did appear to experience notable benefits from…

While the now-discontinued amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failed to show a meaningful effect on disease progression, lung function, or life quality in the Phase 3 PHOENIX clinical trial, ongoing analyses will look at other outcomes such as biomarkers and survival. That’s according…

Storing chemicals such as gasoline, lawn care products, and paints in a garage attached to a home was associated with an increased risk of amyotrophic lateral sclerosis (ALS) in a recent analysis. Researchers believe the findings add to knowledge about environmental exposures — workplace, recreational, or residential — that…

Columbia University researchers will use a $15 million federal grant to design individualized gene therapies for nine people with ultra-rare genetic forms of amyotrophic lateral sclerosis (ALS). The three-year grant comes from the National Institute of Neurological Disorders and Stroke’s (NINDS) Ultra-rare Gene-based Therapy (URGenT) Network, a program…